
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - vcxxxx

42 Results

Sort By:

Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation

Patient conditioning is a critical initial step in hematopoietic stem and progenitor cell (HSPC) transplantation procedures to enable marrow engraftment of infused cells. Conditioning regimens have traditionally been achieved by delivering cytotoxic doses of chemotherapeutic agents and radiation. However, these regimens are associated with significant...

Published: 7/25/2024 | Inventor(s): Daisuke Araki, Diogo Magnani, Zhirui Wang, Andre Larochelle

Keywords(s): 1CXXXX, 2IXXXX, 2JXXXX, Anti-cMPL, Cells, DEPLETION, Divalent, DT-390-Conjugated, hematopoietic, Progenitor, ScFv, Stem, VCXXXX, VPXXXX, WJXXXX, WMXXXX, XAXXXX

Category(s): TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...

Published: 7/25/2024 | Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig

Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

A Diagnostic Kit for Assessing Exposure or Infection by the Koala Family of Retroviruses

This invention relates to a diagnostic kit for assessing exposure to or infection by a koala retrovirus. The kit consists of specific primers and probes for the detection of three distinct subtypes of infectious koala retrovirus and may be useful in various species, including humans, primates, and koalas. A family of infectious koala retroviruses are...

Published: 7/25/2024 | Inventor(s): Wenqin Xu, William Switzer, HaoQiang Zheng, Maribeth Eiden

Keywords(s): ASSESSING, CA1AXX, DA4BXX, diagnostic, Exposure, FAMILY, Gammaretroviruses, Infection, KIT, Koala, Listed LPM Maddox as of 4/15/2015, Ofgammaretroviruses, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, VLXXXX, VOXXXX, WBXXXX, XCXXXX

Category(s): Application > Consumer Products, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

DNA Methylation Based Non-invasive Blood Diagnostic Assay for Precision Cancer Detection and Classification

This technology includes a panel of 46 genomic loci of DNA methylation (represented by CpG dinucleotides on different chromosomes) with application in blood-based cancer screening. The markers robustly distinguish tumor from normal samples using 8 loci and classify 13 different tumor types. Using 39 loci, inventors were able to discriminate between...

Published: 7/25/2024 | Inventor(s): Gennady Margolin, Laura Elnitski

Keywords(s): assay, Based, Blood, CANCER, CLASSIFICATION, Detection, diagnostic, DNA, Humans, Methylation, NON-INVASIVE, PRECISION, VCXXXX, WBXXXX, WIXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Diagnostics, TherapeuticArea > Oncology, Application > Therapeutics

Human Serous Endometrial Cancer Cell Lines CRISPR-edited to knock-in FBXW7 mutations for Use in Cancer related Molecular and Cellular Studies

This technology includes endometrial cancer cell lines for use in molecular and cellular studies to determine the effects of cancer-associated FBXW7 (F-box and WD repeat domain-containing 7) mutations, including but not limited to biochemical studies, proteomic studies, and drug sensitivity/resistance studies. Clustered Regularly Interspaced Palindromic...

Published: 7/25/2024 | Inventor(s): Mary Urick, Daphne Bell

Keywords(s): CANCER, Cell, CRISPR-edited, endometrial, FBXW7, Human, Knock-in, Lines, Mutations, Serous, VCXXXX, WIXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Application > Research Materials

Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment

This technology includes the use of pyridines for anticancer treatment. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer...

Published: 7/25/2024 | Inventor(s): Ajit Jadhav, Diane Luci, Thomas Dexheimer, Anton Simeonov, Nathan Coussens, David Maloney

Keywords(s): CANCER, Novel, PYRIDINES, Their, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Research Materials, TherapeuticArea > Oncology, Application > Therapeutics

Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer

This technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy...

Published: 7/25/2024 | Inventor(s): Sheng Dai, Wei Zheng

Keywords(s): 1, 17-hydroxy, Autophagy, Beclin, CANCER, Cells, COLON, Increased, Inhibitions, Overcomes, Resistance, TRAIL, VCXXXX, WIXXXX, WKXXXX, Wortmannin, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Research Materials, Application > Therapeutics

Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers

The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...

Published: 7/25/2024 | Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao

Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology

Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance

This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...

Published: 7/25/2024 | Inventor(s): Jian-kang Jiang, Craig Thomas

Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials

Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties

This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and...

Published: 7/25/2024 | Inventor(s): Scott Hoyt, Patrick Sutter, Chris Finocchio, Daniel Starczynowski, Gregory Tawa, Craig Thomas

Keywords(s): 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology

1 2 3 4 5

|

|

|

© 2024. All Rights Reserved. Powered by Inteum